By Gina Shaw
A new hemophilia management program launched by Magellan Rx Management in collaboration with the non-profit health plan Health New England has, in its first six months, reduced the average assay of clotting factor dispensed in prophylaxis patients from 5% to 1%, reducing the potential for waste with no breakthrough bleeding among individuals who had a dose reduction.
APRIL 18, 2018